Pfizer ACAT Inhibitor Phase III Underway; Zocor, Lipitor Prepare For Crestor
Executive Summary
Pfizer will receive Phase III data on the anti-atherosclerotic agent avasimibe during 2001, Worldwide Development President Peter Corr told a Pfizer securities analysts meeting Dec. 11 in New York City.
You may also be interested in...
Pfizer/Esperion Deal Reunites Lipitor Team; $1.3 Bil. Buys Two HDL Agents
Pfizer's $1.3 bil. acquisition of Esperion will reunite the Lipitor research team and give Pfizer two more chances to develop a novel mechanism anti-atherosclerotic agent
Pfizer/Esperion Deal Reunites Lipitor Team; $1.3 Bil. Buys Two HDL Agents
Pfizer's $1.3 bil. acquisition of Esperion will reunite the Lipitor research team and give Pfizer two more chances to develop a novel mechanism anti-atherosclerotic agent
Schering-Plough Targets Annual Rate Of 10 Preclinical Compounds By 2005
Schering-Plough expects to move 10 compounds from discovery into preclinical development each year by 2005.